|
1
|
Omar E: Current concepts and future of
noninvasive procedures for diagnosing oral squamous cell carcinoma
- a systematic review. Head Face Med. 11:62015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chestnut C, Subramaniam D, Dandawate P,
Padhye S, Taylor J III, Weir S and Anant S: Targeting major
signaling pathways of bladder cancer with phytochemicals: A review.
Nutr Cancer. 11:1–23. 2020. View Article : Google Scholar
|
|
7
|
Khan T, Ali M, Khan A, Nisar P, Jan SA,
Afridi S and Shinwari ZK: Anticancer plants: A review of the active
phytochemicals, applications in animal models, and regulatory
aspects. Biomolecules. 10:472019. View Article : Google Scholar
|
|
8
|
Kalailingam P, Kannaian B, Tamilmani E and
Kaliaperumal R: Efficacy of natural diosgenin on cardiovascular
risk, insulin secretion, and beta cells in streptozotocin
(STZ)-induced diabetic rats. Phytomedicine. 21:1154–1161. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng L, Yin L, Xu L, Qi Y, Li H, Xu Y,
Han X, Liu K and Peng J: Protective effect of dioscin against
thioacetamide-induced acute liver injury via FXR/AMPK signaling
pathway in vivo. Biomed Pharmacother. 97:481–488. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Xu Y, Qi Y, Xu L, Song S, Yin L,
Tao X, Zhen Y, Han X, Ma X, et al: Protective effects of dioscin
against doxorubicin-induced nephrotoxicity via adjusting
FXR-mediated oxidative stress and inflammation. Toxicology.
378:53–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao L, Tao X, Qi Y, Xu L, Yin L and Peng
J: Protective effect of dioscin against doxorubicin-induced
cardiotoxicity via adjusting microRNA-140-5p-mediated myocardial
oxidative stress. Redox Biology. 16:189–198. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Tao X, Yin L, Xu L, Xu Y, Qi Y,
Han X, Song S, Zhao Y, Lin Y, et al: Protective effects of dioscin
against cisplatin-induced nephrotoxicity via the
microRNA-34a/sirtuin 1 signalling pathway. Br J Pharmacol.
174:2512–2527. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mao Z, Han X, Chen D, Xu Y, Xu L, Yin L,
Sun H, Qi Y, Fang L, Liu K and Peng J: Potent effects of dioscin
against hepatocellular carcinoma through regulating TP53-induced
glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis,
autophagy, and DNA damage. Br J Pharmacol. 176:919–937. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Si L, Zheng L, Xu L, Yin L, Han X, Qi Y,
Xu Y, Wang C and Peng J: Dioscin suppresses human laryngeal cancer
cells growth via induction of cell-cycle arrest and MAPK-mediated
mitochondrial-derived apoptosis and inhibition of tumor invasion.
Eur J Pharmacol. 774:105–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei Y, Xu Y, Han X, Qi Y, Xu L, Xu Y, Yin
L, Sun H, Liu K and Peng J: Anti-cancer effects of dioscin on three
kinds of human lung cancer cell lines through inducing DNA damage
and activating mitochondrial signal pathway. Food Chem Toxicol.
59:118–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo C, Zhang X and Pfeifer GP: The tumor
suppressor RASSF1A prevents dephosphorylation of the mammalian
STE20-like kinases MST1 and MST2. J Biol Chem. 286:6253–6261. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang J, Wu S, Barrera J, Matthews K and
Pan D: The Hippo signaling pathway coordinately regulates cell
proliferation and apoptosis by inactivating Yorkie, the
Drosophila Homolog of YAP. Cell. 122:421–434. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dammann R, Li C, Yoon JH, Chin PL, Bates S
and Pfeifer GP: Epigenetic inactivation of a RAS association domain
family protein from the lung tumour suppressor locus 3p21.3. Nat
Genet. 25:315–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agathanggelou A, Cooper WN and Latif F:
Role of the Ras-association domain family 1 tumor suppressor gene
in human cancers. Cancer Res. 65:3497–508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Q, Song W and Xiao W: Dioscin induces
demethylation of DAPK-1 and RASSF-1alpha genes via the antioxidant
capacity, resulting in apoptosis of bladder cancer T24 cells. EXCLI
J. 16:101–112. 2017.PubMed/NCBI
|
|
22
|
Hamilton G, Yee KS, Scrace S and O'Neill
E: ATM regulates a RASSF1A-dependent DNA damage response. Curr
Biol. 19:2020–2025. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu G, Zhou X, Xing J, Xiao Y, Jin B, Sun
L, Yang H, Du S, Xu H and Mao Y: Identification of RASSF1A promoter
hypermethylation as a biomarker for hepatocellular carcinoma.
Cancer Cell Int. 20:5472020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo C, Tommasi S, Liu L, Yee JK, Dammann R
and Pfeifer GP: RASSF1A is part of a complex similar to the
Drosophila Hippo/Salvador/Lats tumor-suppressor network.
Curr Biol. 17:700–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwam ZG and Judson BL: Improved
prognosis for patients with oral cavity squamous cell carcinoma:
Analysis of the National Cancer Database 1998–2006. Oral Oncol.
52:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Metzger K, Moratin J, Horn D, Pilz M,
Ristow O, Hoffmann J, Freier K, Engel M and Freudlsperger C:
Treatment delay in early-stage oral squamous cell carcinoma and its
relation to survival. J Craniomaxillofac Surg. Feb 12–2021.(Epub
ahead of print). doi: 10.1016/j.jcms.2021.02.007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu B, Xu Y, Xu L, Cong X, Yin L, Li H and
Peng J: Mechanism investigation of dioscin against CCl4-induced
acute liver damage in mice. Environ Toxicol Pharmacol. 34:127–135.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu S, Xu H, Peng J, Wang C, Jin Y, Liu K,
Sun H and Qin J: Potent anti-inflammatory effect of dioscin
mediated by suppression of TNF-α-induced VCAM-1, ICAM-1and EL
expression via the NF-κB pathway. Biochimie. 110:62–72. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsieh MJ, Tsai TL, Hsieh YS, Wang CJ and
Chiou HL: Erratum to: Dioscin-induced autophagy mitigates cell
apoptosis through modulation of PI3K/Akt and ERK and JNK signaling
pathways in human lung cancer cell lines. Arch Toxicol.
91:2495–2496. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao LL, Li FR, Jiao P, Yang MF, Zhou XJ,
Si YH, Jiang WJ and Zheng TT: Paris chinensis dioscin induces G2/M
cell cycle arrest and apoptosis in human gastric cancer SGC-7901
cells. World J Gastroenterol. 17:4389–4395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song X, Wang Z, Liang H, Zhang W, Ye Y, Li
H, Hu Y, Zhang Y, Weng H, Lu J, et al: Dioscin induces gallbladder
cancer apoptosis by inhibiting ROS-Mediated PI3K/AKT signalling.
Int J Biol Sci. 13:782–793. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hsu WH, Lee BH and Pan TM: Effects of red
mold dioscorea on oral carcinogenesis in DMBA-induced hamster
animal model. Food Chem Toxicol. 49:1292–1297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao X, Tao X, Xu L, Yin L, Qi Y, Xu Y,
Han X and Peng J: Dioscin induces apoptosis in human cervical
carcinoma HeLa and SiHa cells through ROS-Mediated DNA damage and
the mitochondrial signaling pathway. Molecules. 21:7302016.
View Article : Google Scholar
|
|
34
|
Guo X and Ding X: Dioscin suppresses the
viability of ovarian cancer cells by regulating the VEGFR2 and
PI3K/AKT/MAPK signaling pathways. Oncol Lett. 15:9537–9542.
2018.PubMed/NCBI
|
|
35
|
Si L, Xu L, Yin L, Qi Y, Han X, Xu Y, Zhao
Y, Liu K and Peng J: Potent effects of dioscin against pancreatic
cancer via miR-149-3P-mediated inhibition of the Akt1 signalling
pathway. Br J Pharmacol. 174:553–568. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hansen CG, Moroishi T and Guan KL: YAP and
TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol.
25:499–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He C, Mao D, Hua G, Lv X, Chen X,
Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al: The
Hippo/YAP pathway interacts with EGFR signaling and HPV
oncoproteins to regulate cervical cancer progression. EMBO Mol Med.
7:1426–1449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ciamporcero E, Shen H, Ramakrishnan S, Yu
Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti
S, et al: YAP activation protects urothelial cell carcinoma from
treatment-induced DNA damage. Oncogene. 35:1541–1553. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen X, Gu W, Wang Q, Fu X, Wang Y, Xu X
and Wen Y: C-MYC and BCL-2 mediate YAP-regulated tumorigenesis in
OSCC. Oncotarget. 9:668–679. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bae JS, Kim SM and Lee H: The Hippo
signaling pathway provides novel anti-cancer drug targets.
Oncotarget. 8:16084–16098. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Z, Xu J, Wu Y, Lei S, Liu H, Meng Q
and Xia Z: Diosgenin inhibited the expression of TAZ in
hepatocellular carcinoma. Biochem Biophys Res Commun.
503:1181–1185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grawenda AM and O'Neill E: Clinical
utility of RASSF1A methylation in human malignancies. Br J Cancer.
113:372–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou SL, Cui J, Fan ZM, Li XM, Li JL, Liu
BC, Zhang DY, Liu HY, Zhao XK, Song X, et al: Polymorphism of A133S
and promoter hypermethylation in Ras association domain family 1A
gene (RASSF1A) is associated with risk of esophageal and gastric
cardia cancers in Chinese population from high incidence area in
northern China. BMC Cancer. 13:2592013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Klacz J, Wierzbicki PM, Wronska A,
Rybarczyk A, Stanislawowski M, Slebioda T, Olejniczak A,
Matuszewski M and Kmiec Z: Decreased expression of RASSF1A tumor
suppressor gene is associated with worse prognosis in clear cell
renal cell carcinoma. Int. J Oncol. 48:55–66. 2016.
|
